Breast Cancer: KOL Insight [2017] [Report Updated: 01062017] Prices from USD $8145

05:29 EDT 1 Jul 2017 | BioPortfolio Report Blog

How is Ibrance faring? Is Kisqali expected to be a threat?

Having dominated the HER2positive breast cancer space for many years, Roche's blockbuster drug Herceptin is likely to face the threat of biosimilar trastuzumab in the coming years; KOLs weigh in on how biosimilar trastuzumab may be accepted by physicians and patients, its potential usage in different settings, as well as its chances to become the preferred agent in the HER2positive space. Meanwhile, KOLs discuss how Roche's Perjeta is setting itself up for expanded use. Experts also give their views on how Pfizer's Ibrance is faring in the HER2negative/HRpositive space and what challenges lie ahead for this drug, including the arrival of Novartis' Kisqali and Eli Lilly's abemaciclib. The potential usage of PARP inhibitors and PD1/PDL1 checkpoint inhibitors in triplenegative breast cancer is also explored. Twelve US and EU KOLs offer their candid insights on these issues and more.

In this 6 US and six EU KOLs offer their candid insights on 6 marketed therapies and 12 pipeline drugs.

Take a tour of the report now:

The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the 6 EU 6 US KOLs are >
Review an extract from the report 1 drug profile >

Top Takeaways

Several biosimilar trastuzumab versions are under regulatory review. How do KOLs view these products and how do they envisage their future use?
Perjeta is under investigation as an adjuvant therapy for HER2positive disease. What impact will the APHINITY study results have?
Neratinib is awaiting approval in the extended adjuvant setting. How do KOLs view this agent and is uptake likely to be significant?
What are Ibrance's chances of approval in other settings? And can Pfizer fend off competition from Kisqali and abemaciclib?
How do the alpha specific PI3 kinase inhibitors, alpelisib and taselisib shape up against the CDK4/6 inhibitors? KOLs offer their views on these agents and how they could be positioned.
Kisqali has received US approval for HER2negative/HRpositive breast cancer. What benefits does this product need to show in order to compete effectively?
KOLs discuss how PARP inhibitors and checkpoint inhibitors may be used in triplenegative breast cancer TNBC. What are KOLs' thoughts on these agents and how do they envisage TNBC to be treated in the future?


Alpelisib is clearly more selective or alpha specific. This should allow for better targeting but we'll see if that pans out clinically. I think we need to be careful with the toxicity of these drugs.EU Key Opinion Leader

There are still studies that need to be completed to address the issue of sequencing of different therapies. The bulk of the evidence does support firstline use with a CDK4/6 inhibitor, but then after you get beyond firstline therapy, it starts to become a bit more confusing. US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

Herceptin trastuzumab; Roche
Kadcyla adotrastuzumab emtansine; Roche
Perjeta pertuzumab; Roche
Tykerb/Tyverb lapatinib; Novartis
Plus 2 more download the full list now >

Phase III

neratinib PB 272; Puma Biotechnology
margetuximab MGAH 22; MacroGenics
Gilotrif/Giotrif afatinib; Boehringer Ingelheim
Kisqali ribociclib; Novartis
Plus 8 more download the full list now >

Sample of KOLs interviewed

KOLs from North America

Dr. Charles L. Vogel, MD. Professor of Clinical Medicine, Division of Haematology/Oncology, Miller School of Medicine, University of Miami, Florida.
Dr. Adam M. Brufsky, MD, PhD. Professor of Medicine at the University of Pittsburgh School of Medicine, Pittsburgh, PA.
Dr. Joyce O'Shaughnessy, MD. Specialises in medical oncology with board certification in both internal medicine and medical oncology. She is a Diplomate of the American Board of Internal Medicine, with subspecialty certification in medical oncology.

KOLs from Europe

Dr. Thomas Bachelot, MD. Head of the Breast Cancer Unit and the Clinical Trial Unit at the Centre Leon Berard, Lyon, France.
Dr. Adrian L. Harris, MD, DPhil. Professor of Medical Oncology at the University of Oxford and Director of the Cancer Research UK Medical Oncology Unit, London, England.
Dr. Ahmad Awada, MD. Head of Medical Oncology Clinic at Jules Bordet Cancer Institute, Brussels, Belgium.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Original Article: Breast Cancer: KOL Insight [2017] [Report Updated: 01062017] Prices from USD $8145


More From BioPortfolio on "Breast Cancer: KOL Insight [2017] [Report Updated: 01062017] Prices from USD $8145"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...